US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

26.14

0.0000

Volume:45

Turnover:1.19K

Market Cap:2.35M

PE:- -

High:26.14

Open:26.14

Low:26.14

Close:26.14

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.09

T/O Rate:0.05%

Dividend:0.45

Dividend Rate:1.72%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics

Celcuity To Participate in Upcoming Investor Conferences

Satellos to Participate in Upcoming Investor Conferences

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

FutureChem sets final issue price for paid-in capital increase

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210

Vogenx initiated with a Buy at Jones

SciSparc subsidiary provides update on SCI-210 trial enrollment

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.

NeuroThera Labs Hires European IR Firm to Expand Investor Reach

Oppenheimer biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

Becton Dickinson announces STANCE clinical trial enrollment milestone

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/NVIB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":26.13584,"timestamp":1789490406550,"preClose":26.13584,"halted":0,"volume":45,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-15 12:43:22 EDT","open":26.13584,"high":26.13584,"low":26.13584,"amount":1186.02414,"amplitude":0,"askPrice":26.3,"askSize":100,"bidPrice":26.23,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":26.13584,"nav":27.319,"aum":2458779,"dividendRate":0.017245,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.415,"preClose":26.3635,"latestTime":"19:18 EDT","volume":62,"amount":1636.581,"timestamp":1789427917315,"change":0.0515,"changeRate":0.001953,"amplitude":0},"volumeRatio":0.088952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.088952,"shares":90001,"dividePrice":0.4507,"high":26.13584,"amplitude":0,"preClose":26.13584,"low":26.13584,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":26.13584,"eps":0,"divideRate":0.017245,"volume":45,"delay":0,"ttmEps":0,"open":26.13584,"prevYearClose":25,"prevWeekClose":27.3696,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.2254,"twentyDayClose":28.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664285768","title":"BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285768","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272819,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4588","NVIB","XBIX","BK4581","BK4007","LENZ","XBI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851222","title":"Celcuity To Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851222?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:30","pubTimestamp":1788265800,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354143/0/en/celcuity-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664085583","title":"Satellos to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664085583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664085583?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative mus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353948/0/en/satellos-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","MEDX","GDOC","NVIB","BK4139","IDNA","MSLE","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVS","LU0211331839.USD","GNOM","BK4007","CNCR","BK4578","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4588","IE0009355771.USD","GDOC","BK4585","BMED","LU0320765489.SGD","IE00B4R5TH58.HKD","TBXU","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","SYNB","LU0208291251.USD","NVIB","IBB","IE0002141913.USD","MEDX","FBT","BK4532","LFSC","IDNA","IBBQ","PPH","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887912","title":"FutureChem sets final issue price for paid-in capital increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887912?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:46","pubTimestamp":1788230764,"startTime":"0","endTime":"0","summary":"FutureChem Co., Ltd. ( ($KR:220100) ) has issued an announcement. FutureChem Co., Ltd., a KOSDAQ-listed radiopharmaceutical and biotech company, ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881893","title":"Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881893","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881893?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:30","pubTimestamp":1788219000,"startTime":"0","endTime":"0","summary":"An Important Step Forward for Access to LEQEMBI for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353756/0/en/canada-s-drug-agency-issues-final-positive-recommendation-supporting-public-reimbursement-of-leqembi-lecanemab-for-early-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","MCI","MEDX","NVIB","HYLG","SOCL","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883188","title":"NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883188?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:37","pubTimestamp":1788208671,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs reported strong enrollment momentum in its SCI-210 clinical trial for ch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","HYLG","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883886","title":"Vogenx initiated with a Buy at Jones","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883886?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207318,"startTime":"0","endTime":"0","summary":"Jones initiated coverage of Vogenx (VOGX) with a Buy rating and $55 price target Vogenx is a clinical-stage metabolic-focused biotech company, with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOGX","NVIB","XBIX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883858","title":"SciSparc subsidiary provides update on SCI-210 trial enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883858","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883858?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207046,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)announced that NeuroThera Labs continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s SCI-210...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","HYLG","BK4007","MEDX","NVIB","SPRC","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831883","title":"PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831883","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831883?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:05","pubTimestamp":1788206710,"startTime":"0","endTime":"0","summary":"PMV Pharmaceuticals (PMVP) announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMVP","NVIB","MEDX","GDOC","BK4139","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","PINK","LFSC","BK4139","NVIB","TECB","IEIH","BMED","BBP","BK4585","PSCH","RSPH","SYNB","TBXU","BK4588","IBB","MRNX","GNMX","IDNA","IYH","XLVX","BK4007","MEDI","PTGX","FRTY","TAK","GDOC","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663404203","title":"Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103","url":"https://stock-news.laohu8.com/highlight/detail?id=2663404203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663404203?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:35","pubTimestamp":1788118510,"startTime":"0","endTime":"0","summary":"Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hyp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","NVIB","BK4007","HYLG","LENZ","BK4139","GDOC","MEDX","TENX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","NVIB","PSCH","MRNX","BBP","TECB","BMED","BK4588","GNMX","LABU","IBB","SYNB","MRNY","RSPH","XLVX","IDNA","BK4585","FRTY","PINK","GDOC","MEDI","IYH","IEIH","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","NVIB","SYNB","BMED","GDOC","LFSC","TECB","IYH","PINK","GNMX","FRTY","IBB","RSPH","BBP","PSCH","MRNY","TBXU","MRNX","TAK","BK4007","BK4585","MEDI","IDNA","LABU","IEIH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663015241","title":"Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015241?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:22","pubTimestamp":1787952120,"startTime":"0","endTime":"0","summary":"Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to interest-rate movements.BioNTech shares slid after the biotech firm scrapped a clinical trial for its mRNA cancer vaccine, marking the second setback this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4581","BK4585","BK4588","XBI","XLV","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705792","title":"Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705792?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:22","pubTimestamp":1787898153,"startTime":"0","endTime":"0","summary":"Repligen recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations and raised its full-year 2026 guidance, highlighting broad year-over-year growth across filtration, chromatography, proteins, and process analytics.\nAn interesting detail is that this operational momentum, accompanied by higher full-year forecasts and rising analyst estimates, may reinforce perceptions of Repligen’s business strength across multiple bioprocessing franchises.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0205193047.USD","BK4121","LU0205194284.USD","RGEN","NVIB","LU1815336091.USD","LU0012050646.USD","XBIX","LU0757428866.USD","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403754","title":"NeuroThera Labs Hires European IR Firm to Expand Investor Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403754?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:02","pubTimestamp":1787878968,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. NeuroThera Labs Inc., a clinical-stage biotech subsidiary of SciSparc Ltd. listed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","NVIB","BBC","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871430","title":"Oppenheimer biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871430?lang=en_us&edition=fundamental","pubTime":"2026-08-28 02:00","pubTimestamp":1787853615,"startTime":"0","endTime":"0","summary":"Biotech Analysts, along with the Co-Director of Stanford Amyloid Cente, discuss the full results from AZN/IONS‘s CARDIO-TTRansform trial on an Anal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4585","NVIB","BK4581","XBIX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085942","title":"AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085942","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085942?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:01","pubTimestamp":1787835660,"startTime":"0","endTime":"0","summary":"Video webcast now availablehere OCALA, Fla., Aug.  27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today announced that it participated in the Virtual Inv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352073/29489/en/aim-immunotech-participates-in-the-virtual-investor-why-now-on-demand-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","NVIB","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662470993","title":"Becton Dickinson announces STANCE clinical trial enrollment milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2662470993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662470993?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:55","pubTimestamp":1787828139,"startTime":"0","endTime":"0","summary":"Becton Dickinson (BDX) announced a milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial eval...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1059921491.USD","GDOC","BK4504","LU0511384066.AUD","LU0878866978.SGD","LU0130103400.USD","LU0433182093.SGD","LU1571399168.USD","LU1854103824.USD","MEDX","BK4082","LU0006061336.USD","LU0266013472.USD","IDNA","BK4585","NVIB","LU0130518102.USD","BK4588","IE00BFXG1179.USD","LU0072461881.USD","LU1150488135.SGD","LU0162691827.USD","LU0477156797.USD","LU0648000940.SGD","LU0289739343.SGD","LU1489326972.SGD","LU0985489474.SGD","BDX","LU0985320562.USD","LU1150488218.USD","LU1201861165.SGD","IHI","LU1894683264.USD","HYLG","LU1894683348.USD","LU1854104046.USD","LU0289961442.SGD","LU0068578508.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":181,"code":"91000000","status":"200"}]}}